Alnylam Pharmaceuticals reported $-277402000 in Net Income for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Acadia Pharmaceuticals ACAD:US $ -113.06M 69.96M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Alnylam Pharmaceuticals ALNY:US $ -277.4M 37.06M
Amgen AMGN:US $ 1317M 159M
Arrowhead Research ARWR:US $ -72046000 116.41M
Avrobio Inc AVRO:US $ -29833000 1.61M
Biocryst Pharmaceuticals BCRX:US $ -58.86M 15.34M
Biomarin Pharmaceutical BMRN:US $ 27.66M 93.13M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Intercept Pharmaceuticals ICPT:US $ -7.53M 9.76M
IONIS PHARMACEUT IONS:US $ -65.17M 289.78M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Moderna Inc MRNA:US 2.2B 1.46B
Neurocrine Biosciences NBIX:US $ -16.9M 30.8M
Novartis NVS:US $ 1694M 528M
Ptc Therapeutics PTCT:US $ -152.09M 25.36M
Regeneron Pharmaceuticals REGN:US $ 852.1M 121.4M
Regulus Therapeutics RGLS:US $ -6.72M 0.41M
Sangamo Biosciences SGMO:US $ -43.17M 0.8M
Sarepta Therapeutics SRPT:US $ -231.48M 126.46M
Takeda 4502:JP Y 105014M 116372M
Ultragenyx Pharmaceutical RARE:US $ -158.16M 5.84M
Vertex Pharmaceuticals VRTX:US $ 810.5M 48.4M
Xencor XNCR:US $ -33.98M 57.57M
YTE INCY:US $ 161.43M 123.44M